Kodiak Sciences is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.25 – an increase of 40.69% over the previous week. Kodiak Sciences employs 109 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.25 |
|---|---|
| 52-week range | $1.92 - $11.60 |
| 50-day moving average | $3.59 |
| 200-day moving average | $4.46 |
| Wall St. target price | $6.80 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.35 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.84 from 2025-04-17
| 1 week (2025-04-15) | 22.94% |
|---|---|
| 1 month (2025-03-21) | -13.41% |
| 3 months (2025-01-23) | -65.82% |
| 6 months (2024-10-23) | -19.77% |
| 1 year (2024-04-22) | -16.96% |
|---|---|
| 2 years (2023-04-21) | -44.85% |
| 3 years (2022-04-22) | 6.36 |
| 5 years (2020-04-22) | 51.09 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -28.66% |
| Return on equity TTM | -84.7% |
| Profit margin | 0% |
| Book value | $2.86 |
| Market Capitalization | $149.8 million |
TTM: trailing 12 months
We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $1.92 up to $11.5999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 2.397. This would suggest that Kodiak Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kodiak Sciences Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.